文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

高流量与中流量氧疗治疗原发性头痛:一项随机对照研究

High or mid-flow oxygen therapy for primary headache disorders: A randomized controlled study.
PubMed 文献 · Am J Emerg Med · 2023-03-29
一句话结论急诊原发性头痛患者,高流量与中流量氧疗在15、30、60分钟VAS评分均优于安慰剂(p<0.001),两者间无显著差异,作者认为可先用中流量氧疗。

该前瞻性、双盲、安慰剂对照、交叉设计随机研究在地区三级医院急诊科开展,纳入104例因原发性头痛就诊的中位年龄35.14±9.1岁患者,每位患者在四次独立急诊就诊中分别接受高流量氧气(15 L/min)、中流量氧气(8 L/min)、高流量室内空气安慰剂(15 L/min)及中流量室内空气安慰剂(8 L/min)。结果显示,氧疗组在15、30、60分钟各控制点的VAS评分均显著低于安慰剂组(p<0.001),差异在30分钟时最大;高流量与中流量疗法之间无显著统计学差异(p>0.05);接受安慰剂治疗的患者更可能再次就诊急诊(p<0.05);高流量与中流量组在再次就诊(p>0.05)及30分钟时镇痛需求(p>0.05)方面无显著差异;氧疗组疼痛持续时间显著更短(p<0.05);接受高流量氧疗的患者在急诊停留时间更短(p<0.001)。作者认为氧疗对中年原发性头痛患者可能是有益的治疗选择,基于高流量与中流量氧疗的结果,可能更适合以中流量氧疗开始治疗。

要点

  • 氧疗组在15、30、60分钟VAS评分均显著低于安慰剂组(p<0.001),差异在30分钟时最大。
  • 高流量(15 L/min)与中流量(8 L/min)氧疗之间VAS评分无显著统计学差异(p>0.05)。
  • 接受安慰剂治疗的患者更可能再次就诊急诊(p<0.05);高流量与中流量组在再次就诊方面无显著差异(p>0.05)。
  • 氧疗组疼痛持续时间显著更短(p<0.05);高流量氧疗组急诊停留时间更短(p<0.001)。
  • 高流量与中流量组在30分钟时镇痛需求无显著差异(p>0.05)。

适用人群与场景

  • 在地区三级医院急诊科因原发性头痛就诊、随后再次急诊就诊时纳入研究的中位年龄35.14±9.1岁患者。

处置流程与药物剂量

  • 四种干预分别在四次独立急诊就诊中给予所有纳入患者:高流量氧气15 L/min、中流量氧气8 L/min、高流量室内空气安慰剂15 L/min、中流量室内空气安慰剂8 L/min。
  • 作者认为,基于高流量与中流量氧疗的结果,可能更适合以中流量氧疗开始治疗。

研究设计与关键结果

  • 前瞻性、双盲、安慰剂对照、交叉设计随机研究,纳入104例原发性头痛患者,中位年龄35.14±9.1岁。
  • 氧疗组在15、30、60分钟各控制点VAS评分均显著低于安慰剂组(p<0.001),差异在30分钟时最大。
  • 高流量与中流量疗法之间VAS评分无显著统计学差异(p>0.05)。
  • 接受安慰剂治疗的患者更可能再次就诊急诊(p<0.05);高流量与中流量组在再次就诊方面无显著差异(p>0.05),30分钟时镇痛需求无显著差异(p>0.05)。
  • 氧疗组疼痛持续时间显著更短(p<0.05);接受高流量氧疗的患者急诊停留时间更短(p<0.001)。

证据类型、等级与局限

  • 证据类型:前瞻性、双盲、安慰剂对照、交叉设计随机研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对急诊原发性头痛患者,氧疗(高流量15 L/min或中流量8 L/min)较安慰剂可降低15、30、60分钟VAS评分(p<0.001),并缩短疼痛持续时间(p<0.05)。
  • 高流量氧疗组急诊停留时间更短(p<0.001),但高流量与中流量在VAS评分、再次就诊及30分钟镇痛需求方面无显著差异(p>0.05)。
  • 作者认为氧疗可能是有益的治疗选择,并认为可能更适合以中流量氧疗开始治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Headache is one of the most common causes of emergency department (ED) visits. High-flow oxygen therapy is becoming more attractive as a treatment option because it is safe, effective, and cheap. We aimed to compare the effectiveness of high and medium-flow oxygen therapies with placebo for treating primary headache disorders among middle-aged patients.

METHODS: This prospective, double-blind, placebo-controlled, crossover designed, randomized study was conducted at a regional tertiary hospital's ED. Patients who were treated for primary headache disorder in the ED were evaluated at the time of diagnosis and subsequently included in the study upon their next ED visit. Four different treatment methods were administered; 1) high-flow oxygen (15 L/min oxygen), 2) medium-flow oxygen (8 L/min oxygen), 3) high-flow room air as placebo (15 L/min room air), 4) medium-flow room air as placebo (8 L/min room air). All four treatment methods were administered to all patients included in the study, at four separate ED visits. Patients' data, including demographics, medical history, additional complaints, Visual Analogue Scale (VAS) score, and physical examination findings were recorded by the treating physician.

RESULTS: One hundred and four patients with a mean age of 35.14 ± 9.1 years, were included in the study. Patients who received oxygen therapy had a significantly lower VAS score at all control points (15, 30, and 60 min) when compared with placebo (p < 0.001). This difference in scores reached its maximum at 30 min. There was not a significant statistical difference between the high-flow or mid-flow therapies (p > 0.05). It was determined that patients who received placebo therapy were more likely to revisit ED (p < 0.05). There was not a significant statistical difference between the high-flow or mid-flow therapy groups in terms of revisit (p > 0.05) and the 30th-minute analgesia requirement (p > 0.05). Pain duration was significantly less in patients who received oxygen therapy (p < 0.05). Patients who received high-flow oxygen therapy spent less time in the ED (p < 0.001).

CONCLUSION: Oxygen therapy could be a beneficial treatment option for middle-aged patients with primary headache disorders. Based on the results obtained from high and mid-flow oxygen therapies, it may be more appropriate to begin treatment with mid-flow oxygen.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kaçer İ, Çağlar A. High or mid-flow oxygen therapy for primary headache disorders: A randomized controlled study. Am J Emerg Med. 2023. PMID: 37003031. doi:10.1016/j.ajem.2023.03.037

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。